cancer-2018-posters-abstracts

2 / 23

Page 38
Notes:
allied
academies
Journal of Medical Oncology and Therapeutics | Volume: 3
July 23-25, 2018 | Moscow, Russia
12th World Cancer Congress
Liver-specific gene delivery using engineered virus-like particles of Hepatitis E Virus
Seung Kew Yoon, Eun Byul Lee, Jung-Hee Kim and Wonhee Hur
The Catholic University of Korea, Republic of Korea
Virus-like particles (VLPs) possess the potential for organ-
specific transport of therapeutic agents owing to their
empty space surrounded by viral capsid proteins and a tropism
similar to those of with the original viruses. However, there
have been few reports on suitable VLPs for target-specific
delivery. Hepatitis E virus (HEV) is one of the hepatotropic
viruses showing remarkable liver tropism. N-terminal truncated
ORF2 (Nt-ORF2) of HEV can form VLPs via self-assembly. In
this study, we investigated whether HEV-LPs could specifically
deliver foreign genes through tropism to the liver. HEV-LPs were
obtained by Nt-ORF2 expression in Huh7 cells transduced with
recombinant baculovirus and were then purified by continuous
density gradient centrifugation. The purified HEV-LPs efficiently
penetrated liver-derived cell lines such as Huh7 cells and SK-
Hep-1 cells. Next, to verify the utilization of HEV-LPs as gene
delivery tools, GFP-encoding plasmids were encapsulated
into HEV-LPs in a disassembly/reassembly procedure. After
encapsulation, EGFP was expressed in only liver-derived cells.
HEV-LPs produced in mammalian cells by transduction with
recombinant baculovirus can encapsulate foreign genes into
the central cavity of HEV-LPs. Moreover, encapsulated foreign
genes can specifically transport and express to liver-derived
cells by property of HEV-LPs. This study may provide valuable
information for the development of novel gene therapy tools
for liver disease.
Speaker Biography
Seung Kew Yoon is now a professor of the division of Hepatology and Gastroenterology,
Department of Internal Medicine, College of Medicine, The Catholic University of
Korea, Seoul, Korea. He earned his MD at the Catholic University of Korea in 1985. He
trained in Hepatology & Gastroenterology at Seoul St.Mary’s Hospital, The Catholic
University of Korea from 1992 to 1994. He then subsequently trained as research
fellow in Molecular Hepatology Laboratory, MGH, Harvard Medical School, Boston,
USA from 1996 to 1998. He has been principal investigator in several International
Multicenter Researches on antiviral therapy against hepatitis virus B & C, and
target therapy for HCC. He holds scientific membership in numerous professional
associations in Korea and is a member of the American Association for the Study of
Liver Diseases (AASLD), EASL and APASL. He served as a secretary general of Korean
Association for the Study of the Liver (KASL) from 2013 to 2015. Also, he served as a
secretary general of APASL STC 2016 in Busan. Now he is a vice president of Korean
Association of Internal Medicine. He works as a Director of Liver Cancer Center in Seoul
St,Mary’s Hospital and Catholic University Liver Research Center. He has published
more than 300 authored and co-authored original articles on the viral hepatitis B and
C, NASH, and HCC. He had also written chapter on molecular diagnostics of HCC in
the textbook “Principles of Molecular diagnostics and personalized cancer medicine”.
e: